Skip to main content
Erschienen in: Supportive Care in Cancer 1/2023

01.01.2023 | Research

The least costly pharmacy for cancer supportive care medications over time: the logistic toxicity of playing catch up

verfasst von: Andrew Etteldorf, Ramy Sedhom, Shannon M. Rotolo, Rachel I. Vogel, Christopher M. Booth, Anne H. Blaes, Beth A. Virnig, Stacie B. Dusetzina, Arjun Gupta

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

No single pharmacy in an urban zip code is consistently the least expensive across medications. If medication prices change differently across pharmacies, patients and clinicians will face challenges accessing affordable medications when refilling medications. This is especially pertinent to people with cancer with multiple fills of supportive care medications over time. We evaluated if the lowest-priced pharmacy for a formulation remains the lowest-priced over time.

Methods

We compiled generic medications used to manage nausea/vomiting (14 formulations) and anorexia/cachexia (12 formulations). We extracted discounted prices in October 2021 and again in March 2022 for a typical fill at 8 pharmacies in Minneapolis, Minnesota, USA (zip code 55,414) using GoodRx.com. We examined how prices changed across formulations and pharmacies over time.

Results

Data were available for all 208 possible pharmacy-formulation combinations (8 pharmacies × 26 formulations). For 172 (83%) of the 208 pharmacy-formulation combinations, the March 2022 price was within 20% of the October 2021 price. Across pharmacy-formulation combinations, the price change over time ranged from − 76 to + 292%. For 12 (46%) of the 26 formulations, at least one pharmacy with the lowest price in October 2021 no longer was the least costly in March 2022. For one formulation (dronabinol tablets), the least expensive pharmacy became the most expensive, with an absolute and relative price increase of a fill of $22 and 85%.

Conclusion

For almost half of formulations studied, at least one pharmacy with the lowest price was no longer the least costly a few months later. The lowest price for a formulation (across pharmacies) could also change considerably. Thus, even if a patient accesses the least expensive pharmacy for a medication, they may need to re-check prices across all pharmacies with each subsequent fill to access the lowest prices. In addition to safety concerns, directing medications to and accessing medications at multiple pharmacies can add time and logistic toxicity to patients with cancer, their care partners, prescribers, and pharmacy teams.
Literatur
3.
Zurück zum Zitat Desai N et al (2022) Estimated out-of-pocket costs for cancer-directed and supportive care medications for older adults with advanced pancreatic cancer. J Geriatr Oncol 13(5):754–757CrossRef Desai N et al (2022) Estimated out-of-pocket costs for cancer-directed and supportive care medications for older adults with advanced pancreatic cancer. J Geriatr Oncol 13(5):754–757CrossRef
4.
Zurück zum Zitat Sedhom R, Chino F, Gupta A (2021) Financial toxicity and cancer care #409. J Palliat Med 24(3):453–454CrossRef Sedhom R, Chino F, Gupta A (2021) Financial toxicity and cancer care #409. J Palliat Med 24(3):453–454CrossRef
8.
Zurück zum Zitat Sedhom R, Samaan A, Gupta A (2021) Caregiver Burden #419. J Palliat Med 24(8):1246–1247CrossRef Sedhom R, Samaan A, Gupta A (2021) Caregiver Burden #419. J Palliat Med 24(8):1246–1247CrossRef
9.
Zurück zum Zitat Chua KP et al (2019) Assessment of prescriber and pharmacy shopping among the family members of patients prescribed opioids. JAMA Netw Open 2(5):e193673CrossRef Chua KP et al (2019) Assessment of prescriber and pharmacy shopping among the family members of patients prescribed opioids. JAMA Netw Open 2(5):e193673CrossRef
11.
Zurück zum Zitat Banerjee R, George M, Gupta A (2021) Maximizing home time for persons with cancer. JCO Oncol Pract 17(9):513–516CrossRef Banerjee R, George M, Gupta A (2021) Maximizing home time for persons with cancer. JCO Oncol Pract 17(9):513–516CrossRef
13.
Zurück zum Zitat Singh S et al (2022) Prevalence and workplace drivers of burnout in cancer care physicians in Ontario Canada. JCO Oncol Pract 18(1):e60–e71CrossRef Singh S et al (2022) Prevalence and workplace drivers of burnout in cancer care physicians in Ontario Canada. JCO Oncol Pract 18(1):e60–e71CrossRef
14.
Zurück zum Zitat Tetzlaff ED et al (2022) Changes in burnout among oncology physician assistants between 2015 and 2019. JCO Oncol Pract 18(1):e47–e59CrossRef Tetzlaff ED et al (2022) Changes in burnout among oncology physician assistants between 2015 and 2019. JCO Oncol Pract 18(1):e47–e59CrossRef
15.
Zurück zum Zitat Haque W et al (2022) Payer-imposed quantity limits for antiemetics: everybody hurts. JCO Oncol Pract 18(5):313–317CrossRef Haque W et al (2022) Payer-imposed quantity limits for antiemetics: everybody hurts. JCO Oncol Pract 18(5):313–317CrossRef
16.
Zurück zum Zitat Marcum ZA et al (2014) Effect of multiple pharmacy use on medication adherence and drug-drug interactions in older adults with Medicare Part D. J Am Geriatr Soc 62(2):244–252CrossRef Marcum ZA et al (2014) Effect of multiple pharmacy use on medication adherence and drug-drug interactions in older adults with Medicare Part D. J Am Geriatr Soc 62(2):244–252CrossRef
21.
Zurück zum Zitat Giap F, Chino F, Gupta A (2022) Systems-level changes to address financial toxicity in cancer care. JCO Oncol Pract 18(4):310–311CrossRef Giap F, Chino F, Gupta A (2022) Systems-level changes to address financial toxicity in cancer care. JCO Oncol Pract 18(4):310–311CrossRef
22.
Zurück zum Zitat Everson J, Frisse ME, Dusetzina SB (2019) Real-time benefit tools for drug prices. JAMA 322(24):2383–2384CrossRef Everson J, Frisse ME, Dusetzina SB (2019) Real-time benefit tools for drug prices. JAMA 322(24):2383–2384CrossRef
23.
Zurück zum Zitat Hussaini SMQ et al (2022) Intermediate strengths and inflated prices: the story of transdermal fentanyl patches. J Palliat Med 25(9):1335–1337CrossRef Hussaini SMQ et al (2022) Intermediate strengths and inflated prices: the story of transdermal fentanyl patches. J Palliat Med 25(9):1335–1337CrossRef
24.
Zurück zum Zitat Teasdale B et al (2022) Trends and determinants of retail prescription drug costs. Health Serv Res 57(3):548–556CrossRef Teasdale B et al (2022) Trends and determinants of retail prescription drug costs. Health Serv Res 57(3):548–556CrossRef
Metadaten
Titel
The least costly pharmacy for cancer supportive care medications over time: the logistic toxicity of playing catch up
verfasst von
Andrew Etteldorf
Ramy Sedhom
Shannon M. Rotolo
Rachel I. Vogel
Christopher M. Booth
Anne H. Blaes
Beth A. Virnig
Stacie B. Dusetzina
Arjun Gupta
Publikationsdatum
01.01.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-022-07472-x

Weitere Artikel der Ausgabe 1/2023

Supportive Care in Cancer 1/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.